Fostamatinib
- Generic Name
- Fostamatinib
- Brand Names
- Tavalisse, Tavlesse
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26FN6O9P
- CAS Number
- 901119-35-5
- Unique Ingredient Identifier
- SQ8A3S5101
- Background
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has also been granted orphan drug status by the FDA .
Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.
- Indication
用于治疗对既往治疗反应不足的慢性免疫性血小板减少症（ITP）成年患者的血小板减少症。
- Associated Conditions
- Chronic immune thrombocytopenia
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 457
- Registration Number
- NCT00665925
- Locations
- 🇺🇸
North Carolina Arthritis & Allergy Care Center, Raleigh, North Carolina, United States
🇧🇬DCC "Sv. Anna" Sofia, Sofia, Bulgaria
🇨🇴Unidad Medica Torre Plaza, Medellín, Antioquia, Colombia
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 219
- Registration Number
- NCT00665626
- Locations
- 🇺🇸
RASF-Clinical Research Center, Boca Raton, Florida, United States
🇺🇸The Osteoporosis & Clinical Trials Center, Hagerstown, Maryland, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT00446095
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT00326339
- Locations
- 🇲🇽
Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, JA, Mexico
🇲🇽Arke Estudios Clinicos, S.A. de C.V., Ciudad Mexico, DF, Mexico
🇲🇽Centro Médico DALINDE, Mexico, Distrito Federal, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.